Protagonist Therapeutics (PTGX) to Release Earnings on Friday

Protagonist Therapeutics (NASDAQ:PTGX) is anticipated to release its Q4 2025 results before the market opens on Friday, February 20th. Analysts expect Protagonist Therapeutics to post earnings of ($0.53) per share for the quarter. Interested persons are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Friday, February 20, 2026 at 12:30 PM ET.

Protagonist Therapeutics Stock Down 1.9%

Shares of NASDAQ:PTGX opened at $81.93 on Friday. Protagonist Therapeutics has a fifty-two week low of $33.70 and a fifty-two week high of $96.54. The firm’s 50 day moving average price is $85.43 and its 200 day moving average price is $74.47. The stock has a market cap of $5.12 billion, a price-to-earnings ratio of 132.15 and a beta of 2.26.

Insider Activity

In other Protagonist Therapeutics news, CFO Asif Ali sold 46,203 shares of the business’s stock in a transaction on Tuesday, January 27th. The shares were sold at an average price of $83.13, for a total transaction of $3,840,855.39. Following the sale, the chief financial officer directly owned 60,320 shares in the company, valued at approximately $5,014,401.60. The trade was a 43.37% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director William D. Waddill sold 20,000 shares of the business’s stock in a transaction dated Friday, February 6th. The stock was sold at an average price of $83.68, for a total transaction of $1,673,600.00. Following the sale, the director directly owned 7,825 shares in the company, valued at approximately $654,796. This represents a 71.88% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 185,167 shares of company stock valued at $15,405,639. Corporate insiders own 4.90% of the company’s stock.

Hedge Funds Weigh In On Protagonist Therapeutics

Hedge funds have recently made changes to their positions in the stock. Royal Bank of Canada raised its position in shares of Protagonist Therapeutics by 30.6% during the 1st quarter. Royal Bank of Canada now owns 9,964 shares of the company’s stock worth $482,000 after purchasing an additional 2,334 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Protagonist Therapeutics by 0.9% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,403 shares of the company’s stock worth $1,810,000 after buying an additional 348 shares during the period. Millennium Management LLC increased its position in Protagonist Therapeutics by 283.6% in the first quarter. Millennium Management LLC now owns 134,269 shares of the company’s stock worth $6,493,000 after buying an additional 99,269 shares during the period. Arrowstreet Capital Limited Partnership bought a new stake in Protagonist Therapeutics in the second quarter valued at $987,000. Finally, Guggenheim Capital LLC boosted its holdings in shares of Protagonist Therapeutics by 1.6% during the second quarter. Guggenheim Capital LLC now owns 19,208 shares of the company’s stock valued at $1,062,000 after acquiring an additional 303 shares during the period. Institutional investors and hedge funds own 98.63% of the company’s stock.

Analysts Set New Price Targets

PTGX has been the subject of several analyst reports. JPMorgan Chase & Co. upped their price objective on Protagonist Therapeutics from $68.00 to $81.00 and gave the stock an “overweight” rating in a research report on Friday, November 7th. Citigroup boosted their target price on Protagonist Therapeutics from $98.00 to $115.00 and gave the stock a “buy” rating in a research note on Monday, December 8th. Jefferies Financial Group upped their price target on Protagonist Therapeutics from $95.00 to $118.00 and gave the company a “buy” rating in a report on Monday, February 2nd. Citizens Jmp raised their price objective on shares of Protagonist Therapeutics from $69.00 to $102.00 and gave the stock a “market outperform” rating in a report on Friday, November 7th. Finally, Truist Financial boosted their price objective on shares of Protagonist Therapeutics from $88.00 to $110.00 and gave the stock a “buy” rating in a research report on Monday, January 5th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $91.64.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.